Cytomegalovirus vectors for a prophylactic HIV vaccine
An engineered cytomegalovirus vector could provide the backbone for a prophylactic HIV vaccine
A spread-deficient cytomegalovirus carrying SIV antigens evoked long-term protective immunity against successive SIV infections in monkeys, suggesting that a prophylactic HIV vaccine can be developed in humans using a similar strategy.
While academics and companies are focusing on harnessing the immune system to eliminate the HIV virus postinfection, they are also looking at ways to prevent HIV infection.
Antiretroviral drug Truvada emtricitabine/tenofovir from Gilead Sciences Inc.